查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589740

末期腎病市場：按治療、診斷和最終用戶分類 - 全球預測 2025-2030

End Stage Renal Disease Market by Treatment (Dialysis, Transplantation), Diagnosis (Blood Tests, Imaging Tests, Kidney Sample Removal For Testing), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年末期腎病市場價值為462.9億美元，預計2024年將達到530.9億美元，複合年成長率為14.80%，到2030年將達到1216.5億美元。

末期腎病 (ESRD) 是慢性腎臟病的最後階段，也是最嚴重的階段，此時腎臟功能僅達到正常功能的 10% 至 15% 左右。 ESRD 的治療需要維持生命，其中透析和腎臟移植至關重要。主要用途包括血液透析機、腹膜透析和移植，最終用途包括醫院、診所和獨立透析中心。市場成長主要是由高血壓和糖尿病盛行率上升和患者數量增加所推動的。家庭透析治療解決方案等技術進步和政府改善醫療基礎設施的努力正在推動需求。為新興市場開發用於透析的遠端醫療和遠端監控技術以及負擔得起的透析設備的機會也在擴大。主要研究興趣包括加強與醫療保健提供者的夥伴關係以及投資人工腎臟研究。

主要市場統計
基準年[2023] 462.9億美元
預測年份 [2024] 530.9億美元
預測年份 [2030] 1216.5億美元
複合年成長率（%） 14.80%

然而，成長並非沒有挑戰。市場擴張受到透析和移植成本高昂以及獲得合適器官的機會有限的限制。監管障礙和嚴格的合規要求使情況更加複雜。此外，缺乏熟練的專業人才也是一大障礙。創新包括攜帶式和穿戴式式透析機、人工智慧在預測性患者照護中的整合，以及用於腎臟修復的再生醫學技術。減少透析副作用和改善長期患者預後的研究也可能提供競爭優勢。該市場的特點是技術快速發展以及現有和新興參與者之間的競爭日益激烈。對公司來說，策略聯盟和併購被認為是提高市場佔有率的潛在途徑。專注於以患者為中心的解決方案和成本效率的公司可能在這個重要的醫療保健領域擁有競爭優勢。

市場動態：快速發展的末期腎病市場的關鍵市場洞察

供需的動態交互作用正在改變末期腎病市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 慢性腎臟病病患者增加
    • 患有高血壓和糖尿病的老年人口不斷增加
    • 生活方式的改變和加工食品的消費增加
  • 市場限制因素
    • 併發症的風險
  • 市場機會
    • 介紹新的技術增強產品
    • 增加對研發活動的投資以及製造商之間的合作
  • 市場挑戰
    • 新醫療設備核准的嚴格監管通訊協定

波特五力：駕馭末期腎臟病市場的策略工具

波特的「五力」框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解末期腎臟病市場的外部影響

外部宏觀環境因素在塑造末期腎臟病市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解末期腎病市場的競爭格局

末期腎病市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣末期腎病市場供應商的績效評估

FPNV 定位矩陣是評估末期腎臟病市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了末期腎臟病市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對末期腎臟病市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性腎臟病病患者增加
      • 患有高血壓和糖尿病的老年人越來越多
      • 生活方式的改變和加工食品消費的增加
    • 抑制因素
      • 併發症的風險
    • 機會
      • 新技術增強產品介紹
      • 增加對研發活動的投資以及製造商之間的合作
    • 任務
      • 新設備核准的嚴格監管通訊協定
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療分類的末期腎臟病市場

  • 透析
    • 血液透析機
    • 腹膜透析
    • 穿戴式人工腎
  • 移植

第7章 末期腎病診斷市場

  • 驗血
  • 影像檢查
  • 收集腎臟樣本進行檢測
  • 尿液檢查

第8章末期腎病市場：依最終用戶分類

  • 透析中心
  • 醫院/診所
  • 研究/學術機構

第9章美洲末期腎病市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太末期腎臟病市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲末期腎臟病市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Amgen Inc.
  • Asahi Kasei Medical Co., Ltd.
  • AstraZeneca
  • B. Braun SE
  • Baxter International, Inc.
  • Becton, Dickinson and Company
  • Bristol-Myers Squibb Company
  • Davita Healthcare Partners Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • GlaxoSmithKline PLC
  • Kissei Pharmaceutical Co., Ltd
  • Medtronic PLC
  • Nikkiso Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-DA46DD749C68

The End Stage Renal Disease Market was valued at USD 46.29 billion in 2023, expected to reach USD 53.09 billion in 2024, and is projected to grow at a CAGR of 14.80%, to USD 121.65 billion by 2030.

End Stage Renal Disease (ESRD) represents the final and most severe stage of chronic kidney disease, where kidneys can only function at roughly 10-15% of their normal capacity. The necessity of treatments for ESRD is driven by their life-sustaining nature, where dialysis or kidney transplantation becomes imperative. The primary applications include hemodialysis, peritoneal dialysis, and transplantation, with the end-use scope encompassing hospitals, clinics, and independent dialysis centers. Market growth is largely influenced by rising incidences of hypertension and diabetes, leading to an increased patient base. Advancements in technology, such as home-based dialysis solutions, and government initiatives toward improved healthcare infrastructure amplify demand. Opportunities abound in telehealth and remote monitoring technologies for dialysis, as well as in developing affordable dialysis equipment for emerging markets. Key recommendations include enhancing partnerships with healthcare providers and investing in research for artificial kidneys.

KEY MARKET STATISTICS
Base Year [2023] USD 46.29 billion
Estimated Year [2024] USD 53.09 billion
Forecast Year [2030] USD 121.65 billion
CAGR (%) 14.80%

However, growth is not without challenges. High costs of dialysis and transplants, coupled with limited access to suitable organs, constrain market expansion. Regulatory hurdles and stringent compliance requirements further complicate the landscape. Additionally, the scarcity of skilled professionals poses a significant barrier. Innovation should target portable and wearable dialysis devices, integration of AI in predictive patient care, and regenerative medicine techniques for kidney repair. Research into reducing the side effects of dialysis and improving long-term patient outcomes can also offer competitive advantages. The market is characterized by rapidly evolving technologies and heightened competition among established and emergent players. For businesses, strategic alliances, and mergers & acquisitions stand out as potential paths to strengthen market presence. Companies that focus on patient-centric solutions and cost-effectiveness will likely command a competitive edge in this crucial healthcare segment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving End Stage Renal Disease Market

The End Stage Renal Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Proliferation in number of people suffering from chronic kidney disease
    • Growing geriatric population with hypertension and diabetes
    • Increasing lifestyle changes and consumption of processed food
  • Market Restraints
    • Risk of complications
  • Market Opportunities
    • Introduction of new technologically enhanced products
    • Increasing investment in research and development activities coupled with collaborations among manufacturers
  • Market Challenges
    • Stringent regulatory protocols for the approval of new devices

Porter's Five Forces: A Strategic Tool for Navigating the End Stage Renal Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the End Stage Renal Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the End Stage Renal Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the End Stage Renal Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the End Stage Renal Disease Market

A detailed market share analysis in the End Stage Renal Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the End Stage Renal Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the End Stage Renal Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the End Stage Renal Disease Market

A strategic analysis of the End Stage Renal Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the End Stage Renal Disease Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Asahi Kasei Medical Co., Ltd., AstraZeneca, B. Braun SE, Baxter International, Inc., Becton, Dickinson and Company, Bristol-Myers Squibb Company, Davita Healthcare Partners Inc., Fresenius Medical Care AG & Co. KGaA, GlaxoSmithKline PLC, Kissei Pharmaceutical Co., Ltd, Medtronic PLC, Nikkiso Co., Ltd., Pfizer Inc., and Sanofi SA.

Market Segmentation & Coverage

This research report categorizes the End Stage Renal Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Dialysis and Transplantation. The Dialysis is further studied across Hemodialysis, Peritoneal Dialysis, and Wearable Artificial Kidney.
  • Based on Diagnosis, market is studied across Blood Tests, Imaging Tests, Kidney Sample Removal For Testing, and Urine Tests.
  • Based on End-User, market is studied across Dialysis Centres, Hospital & Clinics, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Proliferation in number of people suffering from chronic kidney disease
      • 5.1.1.2. Growing geriatric population with hypertension and diabetes
      • 5.1.1.3. Increasing lifestyle changes and consumption of processed food
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of complications
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new technologically enhanced products
      • 5.1.3.2. Increasing investment in research and development activities coupled with collaborations among manufacturers
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory protocols for the approval of new devices
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. End Stage Renal Disease Market, by Treatment

  • 6.1. Introduction
  • 6.2. Dialysis
    • 6.2.1. Hemodialysis
    • 6.2.2. Peritoneal Dialysis
    • 6.2.3. Wearable Artificial Kidney
  • 6.3. Transplantation

7. End Stage Renal Disease Market, by Diagnosis

  • 7.1. Introduction
  • 7.2. Blood Tests
  • 7.3. Imaging Tests
  • 7.4. Kidney Sample Removal For Testing
  • 7.5. Urine Tests

8. End Stage Renal Disease Market, by End-User

  • 8.1. Introduction
  • 8.2. Dialysis Centres
  • 8.3. Hospital & Clinics
  • 8.4. Research & Academic Institutes

9. Americas End Stage Renal Disease Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific End Stage Renal Disease Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa End Stage Renal Disease Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Asahi Kasei Medical Co., Ltd.
  • 3. AstraZeneca
  • 4. B. Braun SE
  • 5. Baxter International, Inc.
  • 6. Becton, Dickinson and Company
  • 7. Bristol-Myers Squibb Company
  • 8. Davita Healthcare Partners Inc.
  • 9. Fresenius Medical Care AG & Co. KGaA
  • 10. GlaxoSmithKline PLC
  • 11. Kissei Pharmaceutical Co., Ltd
  • 12. Medtronic PLC
  • 13. Nikkiso Co., Ltd.
  • 14. Pfizer Inc.
  • 15. Sanofi SA

LIST OF FIGURES

  • FIGURE 1. END STAGE RENAL DISEASE MARKET RESEARCH PROCESS
  • FIGURE 2. END STAGE RENAL DISEASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. END STAGE RENAL DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. END STAGE RENAL DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. END STAGE RENAL DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. END STAGE RENAL DISEASE MARKET DYNAMICS
  • TABLE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY WEARABLE ARTIFICIAL KIDNEY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY KIDNEY SAMPLE REMOVAL FOR TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY URINE TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. END STAGE RENAL DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. END STAGE RENAL DISEASE MARKET, FPNV POSITIONING MATRIX, 2023